Wei-Hao Chen

Wei-Hao Chen

Auto-generated profile, based on publicly available information

Wei-Hao Chen

School of Traditional Chinese Medicine, Jinan University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
YXYa Xiao
Ya Xiao
WCWeihao Chen
Weihao Chen
RCRuixue Chen
Ruixue Chen
ALAnling Luo
Anling Luo
DCDayi Chen
Dayi Chen
WTWei Tan
Wei Tan
Objective. Gestational diabetes mellitus (GDM) is a pathological condition, affecting an increasing number of pregnant women worldwide. Safe and effective treatment for GDM is very important for the public health. In this study, we utilized a high‐fat diet‐induced GDM model to evaluate the effects of LBP on GDM and examined the changes of exosomal microRNA expression profiling to decipher the potential underlying mechanism of LBP. Methods. Female C57BL/6J mice were fed a control diet, HFD, or 150 mg/kg LBP‐supplemented HFD for 6 weeks before conception and throughout gestation. Oral glucose tolerance test and plasma lipid levels were determined, and liver histopathology was assessed. Sequencing was used to define the microRNA expression profiling of plasma exosomes in the three groups of mice, and protein expression levels of the candidate target genes were analyzed. Results. LBP significantly relieved glucose intolerance, abnormal plasma lipid levels, and pathomorphological changes of liver histopathology in HFD‐induced GDM mice. Moreover, we found that this effect of LBP was mediated by downregulation of the increase of 6 miRNAs (miR‐93‐3p, miR‐188‐5p, miR‐466k, miR‐1188‐5p, miR‐7001‐3p, and miR‐7115‐5p) and reversing the increase of the protein expression of CPT1A, which is the target gene of miR‐188‐5p. Conclusions. Our findings provide novel insights into the biological activities of LBP in the treatment of GDM.

19 July 2019 in BMC Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
YCYunfei Cai
Yunfei Cai
QLQiuer Liang
Qiuer Liang
WCWeihao Chen
Weihao Chen
MCMinghao Chen
Minghao Chen
CRChen Ruixue
Chen Ruixue
LCLiguo Chen
Liguo Chen
To evaluate the effectiveness and safety of HuoXueHuaYu (HXHY) therapy in treating nonalcoholic fatty liver disease (NAFLD) through a systematic review and meta-analysis. We performed comprehensive searches on Embase, Pubmed, Cochrane Library, CNKI, VIP and Wanfang databases up to June 2017 for randomized controlled trials using HXHY in the treatment of NAFLD compared with conventional treatment. This meta-analysis included 13 studies involving 1429 patients which 775 patients belonged to HXHY group and 654 patients belonged to conventional treatment group. The results of meta-analysis showed that HXHY can significantly improve B ultrasonic level (OR = 2.33; 95% CI:1.60, 3.40; P < 0.00001) of NAFLD compared with conventional treatment. As to lipids, HXHY was tested to be better on reduction of total cholesterol (TC) (MD = -0.38, 95% CI: − 0.48, − 0.29; P < 0.00001) and triglyceride (TG) (MD = -0.31; 95% CI: − 0.37, − 0.24; P < 0.00001) than conventional treatment. HXHY also had a greater beneficial effect on liver function in reducing alanine transaminase (ALT) (MD = -1.69; 95% CI: − 2.24, − 1.14; P < 0.00001) and aspartate transaminase (AST) (MD = -22.53; 95% CI: − 33.16, − 11.90; P < 0.00001) compared with conventional treatment. HXHY can also significantly improve the effective rate (OR = 3.55; 95% CI:2.65, 4.76; P < 0.00001) compared with conventional treatment. No serious adverse reactions were reported. HXHY seems to be an effective and safe therapy for NAFLD. It is suggested that further study of HXHY in the treatment of NAFLD requires trials with rigorous design, multicenter, large-scale and high-quality worldwide.

6 November 2019 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
LPLiu Pu
Liu Pu
WCWei-Hao Chen
Wei-Hao Chen
LCLu-Xi Cao
Lu-Xi Cao
KWKun-Ji Wu
Kun-Ji Wu
SCShu-Lian Chen
Shu-Lian Chen
YZyimin Zhang
yimin Zhang
Objectives. To evaluate the efficacy and safety of compound Kushen injection (CKI) combined with chemo treatment (chemo) for non-small-cell lung cancer (NSCLC). Methods. We systematically searched the literature published in seven databases, including Embase, PubMed, central, MEDLINE, CNKI, Wanfang, and VIP, from their inception to April 2019 for all randomized controlled trials (RCTs) comparing CKI plus chemo with chemo alone in patients with NSCLC. Our main end point was clinical efficiency and the secondary outcomes were Karnofsky performance score (KPS), immune function, and adverse events. The Cochrane risk of bias tool was applied for quality assessment. Results. 10 studies involving 1019 participants were included. The clinical response rate (relative risk (RR) = 1.21, 95% confidence interval (CI): 1.06 to 1.37; P=0.003), KPS (RR = 2.18, 95% CI: 1.49 to 3.17; P<0.0001), immune function (mean differences (MD) = 0.82, 95% CI: 0.12 to 1.52; P=0.02) and adverse effects (RR = 0.67, 95% CI: 0.60 to 0.74; P<0.00001) in the CKI plus chemo group showed significant differences when compared with chemo alone. Conclusions. CKI combined with chemo can improve clinical efficiency, KPS, and immune function and reduce adverse reactions in patients with NSCLC when compared with chemo alone. However, more rigorously designed RCTs are needed to validate this benefit, as some of the included RCTs are of low methodological quality.

1 January 2003
Verified
Conference Paper
Closed access
SCShih-Nung Chen
Shih-Nung Chen
JTJ.J.P. Tsai
J.J.P. Tsai
WCWei-Hao Chen
Wei-Hao Chen
Cancer has now become the major disease threatening people's health. That is why research on the factor causing cancer has become significant. Although biomedical researchers can obtain a lot of related biomedical literature through a search engine, they also have to face the problem of information overload as well. We propose an intelligent agent system regarding the data mining of biomedical literature, hoping to provide assistance. According to the type of cancer user enter, the system will automatically combine it with LOH (loss of heterozygosity) or CGH (comparative genomic hybridization), and then search for related biomedical literatures from the PubMed. And then the retrieved literatures will be categorized using the decision tree, with which the cancer-related genes can be mined at the same time. The method can help mine important information from biomedical literatures and thus helps users to gain quick and easy access to important information. Also, this method can be applied to other diseases.